{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:33Z","timestamp":1792119693695,"version":"4.4.0"},"reference-count":132,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The advent of immune checkpoint inhibitors (ICIs) and targeted therapies has revolutionized advanced cutaneous melanoma care, shifting it from an acutely fatal illness to a chronic, manageable condition. While extending survival, these modern therapies introduce a new spectrum of persistent immune-related adverse events (irAEs) and long-term toxicities. This study aims to explore the \u201cToxicity-HRQoL Paradox\u201d to comprehensively evaluate the true price of survival across the melanoma treatment continuum. Methods: This narrative review, based on a systematic database search, synthesizes quantitative patient-reported outcomes, health-related quality of life (HRQoL) trajectories, and health-economic data. It evaluates the impact of surgical, regional, and modern systemic therapies utilizing data derived from validated instruments, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), EuroQol 5 Dimensions (EQ-5D), Functional Assessment of Cancer Therapy-Melanoma (FACT-M), and comprehensive score for financial toxicity (COST). Results: Historically, extensive locoregional surgeries and high-dose interferons caused profound, debilitating drops in physical and overall QoL. Today, modern systemic therapies are associated with high rates of severe (Grade \u2265 3) acute toxicities and irreversible chronic conditions, such as permanent endocrinopathies. Despite this, global HRQoL frequently remains stable or even improves. This \u201ctoxicity-HRQoL paradox\u201d occurs because the profound psychological relief of durable disease control effectively offsets the physical symptom burden. Furthermore, neoadjuvant ICI approaches demonstrate superior long-term HRQoL by enabling tailored surgical de-escalation. Ultimately, extended survivorship unmasks hidden burdens, revealing high prevalences of fear of cancer recurrence (FCR) (81\u201386%) and substantial financial toxicity. Conclusions: Despite the severe physical toxicities of modern melanoma treatments, the psychological benefit of survival largely preserves overall HRQoL. However, optimizing the modern survivorship experience requires the widespread adoption of melanoma-specific HRQoL tools and proactive, multidisciplinary care models to manage chronic toxicities, psychosocial distress, and financial burdens.<\/jats:p>","DOI":"10.3390\/cancers18162619","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"2619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Acute and Chronic Adverse Events on Quality of Life in Cutaneous Melanoma"],"prefix":"10.3390","volume":"18","author":[{"given":"Ana-Maria Zamfirescu","family":"Deryder","sequence":"first","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"},{"name":"Oncological Institute \u201cAlexandru Trestioreanu\u201d Bucharest, 252 Soseaua Fundeni, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"B\u00eelteanu","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"},{"name":"Faculty of Biology, University of Bucharest, 91-95 Splaiul Independentei, 050095 Bucharest, Romania"},{"name":"Laboratory for Molecular Nanotechnologies, National Institute for Research and Development in Microtechnologies\u2014MT Bucharest, 126A, Erou Iancu Nicolae Street, 077190 Voluntari, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad-Luca","family":"Moga","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3350-7850","authenticated-orcid":false,"given":"Antonia-Ruxandra","family":"Folea","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zamfirescu","sequence":"additional","affiliation":[{"name":"Oncological Institute \u201cAlexandru Trestioreanu\u201d Bucharest, 252 Soseaua Fundeni, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu-Valeriu","family":"Toma","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"},{"name":"Oncological Institute \u201cAlexandru Trestioreanu\u201d Bucharest, 252 Soseaua Fundeni, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serban-Andrei","family":"Marinescu","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"},{"name":"Oncological Institute \u201cAlexandru Trestioreanu\u201d Bucharest, 252 Soseaua Fundeni, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steluta","family":"Barascu","sequence":"additional","affiliation":[{"name":"Oncological Institute \u201cAlexandru Trestioreanu\u201d Bucharest, 252 Soseaua Fundeni, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea-Iren","family":"\u0218erban","sequence":"additional","affiliation":[{"name":"Faculty of Biology, University of Bucharest, 91-95 Splaiul Independentei, 050095 Bucharest, Romania"},{"name":"Department of Preclinical Sciences, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, 105 Splaiul Independentei, 050097 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Anghel","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e29912","DOI":"10.2196\/29912","article-title":"First-Line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?","volume":"7","author":"Abdulkarim","year":"2021","journal-title":"JMIR Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Choi, M.E., Choi, E.J., Jung, J.M., Lee, W.J., Jo, Y.-S., and Won, C.H. (2024). A Narrative Review of the Evolution of Diagnostic Techniques and Treatment Strategies for Acral Lentiginous Melanoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910414"},{"key":"ref_3","first-page":"434","article-title":"Cutaneous Melanoma in the Elderly: Review of a Growing Problem","volume":"110","author":"Paradela","year":"2019","journal-title":"Actas Dermosifiliogr. (Engl. Ed.)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/ahe.10.26","article-title":"Cutaneous Melanoma in the Elderly: Epidemiology and Management","volume":"6","author":"Lam","year":"2010","journal-title":"Aging Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"109921","DOI":"10.1016\/j.ijscr.2024.109921","article-title":"Malignant Melanoma Presenting as Isolated Thoracic Spinal Metastases\u2014Case Report","volume":"121","author":"Letho","year":"2024","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10238-026-02078-7","article-title":"MLANA Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Skin Cutaneous Melanoma","volume":"26","author":"Tang","year":"2026","journal-title":"Clin. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1590\/abd1806-4841.20142540","article-title":"Cutaneous Melanoma: New Advances in Treatment","volume":"89","author":"Foletto","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3332\/ecancer.2019.959","article-title":"Holistic View of Patients with Melanoma of the Skin: How Can Health Systems Create Value and Achieve Better Clinical Outcomes?","volume":"13","author":"Redondo","year":"2019","journal-title":"Ecancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine Compared with Dacarbazine in Patients with Disseminated Malignant Melanoma: A Phase III Study","volume":"22","author":"Avril","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0959-8049(93)90115-V","article-title":"Prognostic Value of Quality of Life Scores in a Trial of Chemotherapy with or without Interferon in Patients with Metastatic Malignant Melanoma","volume":"29","author":"Coates","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/era.11.98","article-title":"Debulking Surgery in Advanced Melanoma","volume":"11","author":"Gajdos","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000203","DOI":"10.1136\/esmoopen-2017-000203","article-title":"Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with Dacarbazine in Patients with MAGE-A3-Positive Metastatic Cutaneous Melanoma: An Open Phase I\/II Study with a First Assessment of a Predictive Gene Signature","volume":"2","author":"Grob","year":"2017","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lebb\u00e9, C., Dutriaux, C., Lesimple, T., Kruit, W., Kerger, J., Thomas, L., Guillot, B., De Braud, F., Garbe, C., and Grob, J.-J. (2020). Pimasertib Versus Dacarbazine in Patients with Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, 12.","DOI":"10.3390\/cancers12071727"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IOP.0b013e3181b8e06f","article-title":"Cutaneous Melanoma Metastatic to the Eyelid and Periocular Skin","volume":"26","author":"Ramirez","year":"2010","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.2002.20.6.1600","article-title":"Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results from an Italian Multicenter Phase III Randomized Clinical Trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12957-024-03335-3","article-title":"Metastatic Melanoma to Small Bowel: Metastasectomy Is Supported in the Era of Immunotherapy and Checkpoint Inhibitors","volume":"22","author":"Wong","year":"2024","journal-title":"World J. Surg. Onc."},{"key":"ref_17","first-page":"458","article-title":"Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-a) in Metastatic Melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clin. Oncol. R. Coll. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","article-title":"Adjuvant Treatment with Pegylated Interferon \u03b1-2a versus Low-Dose Interferon \u03b1-2a in Patients with High-Risk Melanoma: A Randomized Phase III DeCOG Trial","volume":"27","author":"Eigentler","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sorino, C., Iezzi, S., Ciuffreda, L., and Falcone, I. (2024). Immunotherapy in Melanoma: Advances, Pitfalls, and Future Perspectives. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1403021"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lopes, J., Rodrigues, C.M.P., Gaspar, M.M., and Reis, C.P. (2022). Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14.","DOI":"10.3390\/cancers14194652"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10585-018-9913-y","article-title":"Update on Systemic Therapy for Advanced Cutaneous Melanoma and Recent Development of Novel Drugs","volume":"35","author":"Swe","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cncr.32554","article-title":"Quality-of-life Assessment in French Patients with Metastatic Melanoma in Real Life","volume":"126","author":"Kandel","year":"2020","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e036059","DOI":"10.1136\/bmjopen-2019-036059","article-title":"I-Move, a Personalised Exercise Intervention for Patients with Advanced Melanoma Receiving Immunotherapy: A Randomised Feasibility Trial Protocol","volume":"10","author":"Hyatt","year":"2020","journal-title":"BMJ Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: Phase III Study of Adjuvant Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17512433.2019.1650641","article-title":"Is Single versus Combination Therapy Problematic in the Treatment of Cutaneous Melanoma?","volume":"14","author":"Krattinger","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11060-024-04854-5","article-title":"Quality of Life after Stereotactic Radiosurgery for Brain Metastasis: An Assessment from a Prospective National Registry","volume":"171","author":"Pham","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/pon.6184","article-title":"Psychological and Behavioral Symptoms in Patients with Melanoma: A Systematic Review and Meta-analysis","volume":"32","author":"Danielsen","year":"2023","journal-title":"Psycho-Oncology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.005","article-title":"Impact of Immune Checkpoint Inhibitors and Targeted Therapy on Health-Related Quality of Life of People with Stage III and IV Melanoma: A Mixed-Methods Systematic Review","volume":"184","author":"Inderjeeth","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e006629","DOI":"10.1136\/jitc-2022-006629","article-title":"Efficacy and Toxicity of Adjuvant Radiotherapy in Recurrent Melanoma after Adjuvant Immunotherapy","volume":"11","author":"Bhave","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1245\/s10434-016-5263-7","article-title":"The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-Adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients\u2014Results after 1 Year","volume":"23","author":"Damude","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1245\/s10434-020-08758-2","article-title":"The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years","volume":"27","author":"Moncrieff","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13063-019-3453-x","article-title":"Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in Melanoma: Protocol for a Randomised Patient-Focused Pilot Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma","volume":"20","author":"Murchie","year":"2019","journal-title":"Trials"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Naeser, Y., Helgadottir, H., Brandberg, Y., Hansson, J., Olofsson Bagge, R., Elander, N.O., Ingvar, C., Isaksson, K., Flygare, P., and Nilsson, C. (2020). TRIM Study Protocol\u2014A Prospective Randomized Multicenter Trial to Assess the Role of Imaging during Follow-up after Radical Surgery of Stage IIB-C and III Cutaneous Malignant Melanoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07632-4"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00432-024-05981-2","article-title":"Quality of Life under Treatment with the Immune Checkpoint Inhibitors Ipilimumab and Nivolumab in Melanoma Patients. Real-World Data from a Prospective Observational Study at the Skin Cancer Center Kiel","volume":"150","author":"Grote","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_36","first-page":"832","article-title":"Psychosocial Distress and Persistent Adverse Events in Long-term Survivors of Stage IV Melanoma\u2014A Cross-sectional Questionnaire Study","volume":"23","author":"Reitmajer","year":"2025","journal-title":"J. Dtsch. Dermatol. Gesell."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12094-018-1987-0","article-title":"Health-Related Quality of Life Analysis in Stage III Melanoma Patients Treated with Adjuvant Dendritic Cell Therapy","volume":"21","author":"Bloemendal","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"115640","DOI":"10.1016\/j.ejca.2025.115640","article-title":"The Association between Pretreatment Emotional Distress and Response to Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma","volume":"227","author":"Egeler","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mulder, E.E.A.P., De Joode, K., Liti\u00e8re, S., Ten Tije, A.J., Suijkerbuijk, K.P.M., Boers-Sonderen, M.J., Hospers, G.A.P., De Groot, J.W.B., Van Den Eertwegh, A.J.M., and Aarts, M.J.B. (2021). Early Discontinuation of PD-1 Blockade upon Achieving a Complete or Partial Response in Patients with Advanced Melanoma: The Multicentre Prospective Safe Stop Trial. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08018-w"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.12.029","article-title":"Belgian Observational Survival Data (Incidence Years 2004\u20132017) and Expenditure for Innovative Oncology Drugs in Twelve Cancer Indications","volume":"182","author":"Neyt","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-Related Quality of Life with Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): Secondary Outcomes of a Multinational, Randomised, Double-Blind, Phase 3 Trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of Dabrafenib and Trametinib Combination Therapy with Vemurafenib Monotherapy on Health-Related Quality of Life in Patients with Unresectable or Metastatic Cutaneous BRAF Val600-Mutation-Positive Melanoma (COMBI-v): Results of a Phase 3, Open-Label, Randomised Trial","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(24)00338-3","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): Long-Term, Health-Related Quality-of-Life Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"25","author":"Kicinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 Immunotherapeutic as Adjuvant Therapy for Patients with Resected, MAGE-A3-Positive, Stage III Melanoma (DERMA): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(25)00709-0","article-title":"Vibostolimab Coformulated with Pembrolizumab versus Pembrolizumab Alone as Adjuvant Therapy for High-Risk Stage IIB\u2013IV Melanoma (KEYVIBE-010): A Randomised, Double-Blind, Phase 3 Study","volume":"27","author":"Dummer","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mordoh, J., Pampena, M.B., Aris, M., Blanco, P.A., Lombardo, M., Von Euw, E.M., Mac Keon, S., Y\u00e9pez Crow, M., Bravo, A.I., and O\u2019Connor, J.M. (2017). Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette\u2013Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00625"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Pozas, J., Cheruvu, S., Jaganathan, P.P., Ganesan, P., Modi, A., Larkin, J., Cossar, L., Olsson-Brown, A., Johnson, A., and Garbutt, N. (2025). Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. Cancers, 17.","DOI":"10.3390\/cancers17152461"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104443","DOI":"10.1016\/j.critrevonc.2024.104443","article-title":"Adjuvant Anti-PD1 Immunotherapy of Resected Skin Melanoma: An Example of Non-Personalized Medicine with No Overall Survival Benefit","volume":"202","author":"Ochenduszko","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10072-020-04604-1","article-title":"Neuromuscular Complications Following Targeted Therapy in Cancer Patients: Beyond the Immune Checkpoint Inhibitors. Case Reports and Review of the Literature","volume":"42","author":"Demichelis","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/pbc.25983","article-title":"Feasibility of Pegylated Interferon in Children and Young Adults with Resected High-Risk Melanoma","volume":"63","author":"Navid","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Venturi, F., Veronesi, G., Scotti, B., and Dika, E. (2024). Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution. Cancers, 16.","DOI":"10.3390\/cancers16213679"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): Health-Related Quality-of-Life Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/archopht.124.2.226","article-title":"Quality of Life After Iodine 125 Brachytherapy vs Enucleation for Choroidal Melanoma: 5-Year Results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3","volume":"124","author":"Melia","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.14336\/AD.2017.0503","article-title":"Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology","volume":"8","author":"Garcovich","year":"2017","journal-title":"Aging Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/annonc\/mdi146","article-title":"Predictors of Quality of Life in Newly Diagnosed Melanoma and Breast Cancer Patients","volume":"16","author":"Lehto","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","article-title":"Patient Perception of the Benefit of a BRAF Inhibitor in Metastatic Melanoma: Quality-of-Life Analyses of the BREAK-3 Study Comparing Dabrafenib with Dacarbazine","volume":"25","author":"Grob","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejso.2021.09.013","article-title":"Health-Related Quality of Life Using the FACT-M Questionnaire in Patients with Malignant Melanoma: A Systematic Review","volume":"48","author":"Wesslau","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1245\/s10434-016-5103-9","article-title":"Health-Related Quality of Life for Patients Who Have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion","volume":"23","author":"Bagge","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.amjsurg.2017.07.007","article-title":"Health-Related Quality of Life during Trans-Arterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Ocular Melanoma","volume":"214","author":"Rostas","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/13696998.2023.2174748","article-title":"Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Patients with Resected Stage IIB or IIC Melanoma in Switzerland","volume":"26","author":"Bencina","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/jdv.18456","article-title":"Health-related Quality of Life Trajectories in Melanoma Patients after Electrochemotherapy: Real-world Insights from the InspECT Register","volume":"36","author":"Campana","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/annonc\/mdp255","article-title":"A Systematic Review of Health-Related Quality of Life in Cutaneous Melanoma","volume":"20","author":"Cornish","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ajo.2018.03.015","article-title":"Patient-Reported Outcomes and Quality of Life After Treatment of Choroidal Melanoma: A Comparison of Enucleation Versus Radiotherapy in 1596 Patients","volume":"193","author":"Damato","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","article-title":"The Experience of Financial Toxicity among Advanced Melanoma Patients Treated with Immunotherapy","volume":"39","author":"Thom","year":"2021","journal-title":"J. Psychosoc. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1245\/s10434-014-3979-9","article-title":"Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity","volume":"22","author":"Jiang","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1245\/s10434-012-2635-5","article-title":"Illness-Related Distress in Women with Clinically Localized Cutaneous Melanoma","volume":"20","author":"Atkinson","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamadermatol.2018.3409","article-title":"Association of Quality of Life with Surgical Excision of Early-Stage Melanoma of the Head and Neck","volume":"155","author":"Mori","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Manganelli, M., Stabile, G., Scharf, C., Podo Brunetti, A., Paolino, G., Giuffrida, R., Bigotto, G.D., Damiano, G., Mercuri, S.R., and Sallustio, F. (2025). Skin Photodamage and Melanomagenesis: A Comprehensive Review. Cancers, 17.","DOI":"10.3390\/cancers17111784"},{"key":"ref_69","first-page":"CD012974","article-title":"Neoadjuvant Treatment for Stage III and IV Cutaneous Melanoma","volume":"2023","author":"Gorry","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.07.052","article-title":"Health-Related Quality of Life in Melanoma Patients: Impact of Melanoma-Related Limb Lymphoedema","volume":"85","author":"Gjorup","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.21873\/anticanres.16056","article-title":"Surgery, Limb Edema and Health-Related Quality of Life: A Prospective Follow-up Study on Patients with Cutaneous Malignant Melanoma","volume":"42","author":"Heino","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1245\/s10434-024-15149-4","article-title":"Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial","volume":"31","author":"Lee","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1524-4733.2004.74005.x","article-title":"Cost\u2013Utility of Adjuvant High-Dose Interferon Alpha Therapy in Stage III Cutaneous Melanoma in Quebec","volume":"7","author":"Crott","year":"2004","journal-title":"Value Health"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Melanoma Disease Site Group of Cancer Care Ontario\u2019s Program in Evidence-Based Care Systematic Review of Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma","volume":"106","author":"Verma","year":"2006","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Matteucci, M., Pesce, A., Guarino, S., Cassini, D., Cirillo, B., Boselli, C., D\u2019Andrea, V., Artico, M., Forte, F., and Covarelli, P. (2025). Rethinking Lymphadenectomy in Cutaneous Melanoma: From Routine Practice to Selective Indication: A Narrative Review. Medicina, 61.","DOI":"10.20944\/preprints202508.0866.v1"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1245\/s10434-012-2239-0","article-title":"Quality of Life Outcomes after Isolated Limb Infusion","volume":"19","author":"McClaine","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ejso.2006.03.024","article-title":"The Health-Related Quality of Life of Long-Term Survivors of Melanoma Treated with Isolated Limb Perfusion","volume":"33","author":"Noorda","year":"2007","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2017.1286984","article-title":"Topical Immunotherapy with Diphencyprone (DPCP) for in-Transit and Unresectable Cutaneous Melanoma Lesions: An Inaugural Canadian Series","volume":"13","author":"Yeung","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2340\/00015555-3341","article-title":"Electrochemotherapy in Skin Malignancies of Head and Neck Cancer Patients: Clinical Efficacy and Aesthetic Benefits","volume":"99","author":"Bonadies","year":"2019","journal-title":"Acta Derm.-Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ejso.2016.06.399","article-title":"Treatment Efficacy with Electrochemotherapy: A Multi-Institutional Prospective Observational Study on 376 Patients with Superficial Tumors","volume":"42","author":"Campana","year":"2016","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-020-00428-9","article-title":"The Role of Anti-PD-1\/PD-L1 in the Treatment of Skin Cancer","volume":"34","author":"Patrinely","year":"2020","journal-title":"BioDrugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"115710","DOI":"10.1016\/j.ejca.2025.115710","article-title":"Cross-Sectional Study of Long-Term Health-Related Quality of Life in Stage III Melanoma Patients Receiving Neo-Adjuvant versus Adjuvant Immune Checkpoint Inhibitors","volume":"229","author":"Albers","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaad.2020.04.074","article-title":"Anticancer Therapies Associated with Secondary Cutaneous Malignancies: A Review of the Literature","volume":"83","author":"Deutsch","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Mezi, S., Botticelli, A., Scagnoli, S., Pomati, G., Fiscon, G., De Galitiis, F., Di Pietro, F.R., Verkhovskaia, S., Amirhassankhani, S., and Pisegna, S. (2023). The Impact of Drug\u2013Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15184587"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1445-2197.2011.05790.x","article-title":"Quadriceps Keystone Island Flap for Radical Inguinal Lymphadenectomy: A Reliable Locoregional Island Flap for Large Groin Defects: Quadriceps Keystone Flap","volume":"83","author":"Behan","year":"2013","journal-title":"ANZ J. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/01945998211007442","article-title":"Impact of Completion Lymphadenectomy on Quality of Life for Head and Neck Cutaneous Melanoma","volume":"166","author":"Farlow","year":"2022","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jso.70127","article-title":"Pilot Study of Immediate Lymphatic Reconstruction (ILR) During Lymph Node Dissection for Node-Positive Melanoma: Feasibility, Safety, and Early Outcomes","volume":"133","author":"Jonsson","year":"2026","journal-title":"J. Surg. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Fateeva, A., and Chen, S. (2024). Study on the Complex Melanoma. Cancers, 16.","DOI":"10.3390\/cancers16050843"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1245\/s10434-017-5842-2","article-title":"Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications","volume":"24","author":"Morton","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1245\/s10434-009-0602-6","article-title":"Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients with Cutaneous Melanoma","volume":"16","author":"Hoekstra","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1245\/s10434-015-5074-2","article-title":"Melanoma Patient-Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial","volume":"23","author":"Egger","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1245\/s10434-019-07810-0","article-title":"Inguinal and Ilio-Inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life","volume":"26","author":"Henderson","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Carac\u00f2, C., Mozzillo, N., Marone, U., Simeone, E., Benedetto, L., Di Monta, G., Di Cecilia, M.L., Botti, G., and Ascierto, P.A. (2013). Long-Lasting Response to Electrochemotherapy in Melanoma Patients with Cutaneous Metastasis. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-564"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/15384047.2016.1219811","article-title":"A Retrospective Analysis of the Role of Adjuvant Radiotherapy in the Treatment of Cutaneous Melanoma","volume":"17","author":"Baker","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"113601","DOI":"10.1016\/j.ejca.2024.113601","article-title":"Real-World Health-Related Quality of Life Outcomes for Patients with Resected Stage III\/IV Melanoma Treated with Adjuvant Anti-PD1 Therapy","volume":"200","author":"Egeler","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12861","DOI":"10.1002\/cam4.5967","article-title":"Health-Related Quality of Life in Survivors of Advanced Melanoma Treated with Anti-PD1-Based Immune Checkpoint Inhibitors","volume":"12","author":"Looman","year":"2023","journal-title":"Cancer Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ncponc1007","article-title":"Adjuvant Use of Interferon A2b Is Not Justified in Patients with Stage IIb\/III Melanoma","volume":"5","author":"Bajetta","year":"2008","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00002820-200505000-00002","article-title":"Quality-of-Life Evaluation in an Interferon Therapy After Radical Surgery in Cutaneous Melanoma Patients","volume":"28","author":"Rataj","year":"2005","journal-title":"Cancer Nurs."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.1996.14.10.2666","article-title":"Quality-of-Life-Adjusted Survival Analysis of Interferon Alfa-2b Adjuvant Treatment of High-Risk Resected Cutaneous Melanoma: An Eastern Cooperative Oncology Group Study","volume":"14","author":"Cole","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","article-title":"Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial","volume":"33","author":"Mohr","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","article-title":"Phase III Randomized Study of 4 Weeks of High-Dose Interferon-\u03b1-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (Microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group\u2013American College of Radiology Imaging Network Cancer Research Group (E1697)","volume":"35","author":"Agarwala","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/00019053-200422090-00002","article-title":"Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: A review","volume":"22","author":"Crott","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2017.12.020","article-title":"ECCO Essential Requirements for Quality Cancer Care: Melanoma","volume":"122","author":"Wouters","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1007\/s12325-024-02883-0","article-title":"BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and His Oncologist","volume":"41","author":"Finke","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","article-title":"Patient-Reported Outcomes in Patients with Resected, High-Risk Melanoma with BRAFV600E or BRAFV600K Mutations Treated with Adjuvant Dabrafenib plus Trametinib (COMBI-AD): A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Schadendorf","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/bjc.2017.488","article-title":"Health-Related Quality of Life Impact of Cobimetinib in Combination with Vemurafenib in Patients with Advanced or Metastatic BRAFV600 Mutation\u2013Positive Melanoma","volume":"118","author":"Ascierto","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/NCC.0000000000000683","article-title":"Exploring the Experiences of People Treated with Immunotherapies for Advanced Melanoma and Those Caring for Them: \u201cReal-World\u201d Data","volume":"43","author":"Milne","year":"2020","journal-title":"Cancer Nurs."},{"key":"ref_110","first-page":"5663","article-title":"Cross-Sectional Study of Sex Differences in Psychosocial Quality of Life of Long-Term Melanoma Survivors","volume":"29","author":"Vogel","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12529-013-9334-x","article-title":"Quality of Life in Women with Localised Breast Cancer or Malignant Melanoma 2 Years After Initial Treatment: A Comparison","volume":"21","author":"Engel","year":"2014","journal-title":"Int. J. Behav. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdu366","article-title":"Prevalence and Correlates of Unmet Supportive Care Needs in Patients with Resected Invasive Cutaneous Melanoma","volume":"25","author":"Molassiotis","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/bjophthalmol-2013-303635","article-title":"Quality of Life and Cancer-Related Needs in Patients with Choroidal Melanoma","volume":"97","author":"Wiley","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e054337","DOI":"10.1136\/bmjopen-2021-054337","article-title":"Protocol for the Implementation of a Stepped-Care Model to Address Fear of Cancer Recurrence in Patients Previously Diagnosed with Early-Stage (0\u2013II) Melanoma","volume":"12","author":"Thompson","year":"2022","journal-title":"BMJ Open"},{"key":"ref_115","first-page":"308","article-title":"Cancer Treatment and Survivorship Statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oncolo\/oyac266","article-title":"Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy","volume":"28","author":"Atkinson","year":"2023","journal-title":"Oncologist"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.suronc.2016.05.020","article-title":"Sentinel Node Biopsy in Patients with Primary Cutaneous Melanoma of Any Thickness: A Cost-Effectiveness Analysis","volume":"25","year":"2016","journal-title":"Surg. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-025-17040-2","article-title":"Economic Evaluation of Inguinal Versus Ilio-Inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial","volume":"32","author":"Mahumud","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized Response-Directed Surgery and Adjuvant Therapy after Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 Versus 2-Cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Asare, E., Venner, E., Batchelor, H., Sanders, J., Kunk, P., Hedrick, T., Hoang, S., Reilley, M., Le, T., and Friel, C. (2024). Outcomes Associated with Total Neoadjuvant Therapy with Non-Operative Intent for Rectal Adenocarcinoma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1374360"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.35354","article-title":"Top Advances of the Year: Melanoma","volume":"130","author":"Khattak","year":"2024","journal-title":"Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17588359221134087","DOI":"10.1177\/17588359221134087","article-title":"Systemic Adjuvant Therapy for High-Risk Cutaneous Melanoma","volume":"14","author":"Kobeissi","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e006947","DOI":"10.1136\/jitc-2023-006947","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Melanoma, Version 3.0","volume":"11","author":"Pavlick","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus Adjuvant Ipilimumab plus Nivolumab in Macroscopic Stage III Melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Orme, S.E., and Moncrieff, M.D. (2024). A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management. Cancers, 16.","DOI":"10.3390\/cancers16050895"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.1002\/onco.13852","article-title":"Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review","volume":"26","author":"Cornelius","year":"2021","journal-title":"Oncologist"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"De Smedt, J., Van Kelst, S., Boecxstaens, V., Stas, M., Bogaerts, K., Vanderschueren, D., Aura, C., Vandenberghe, K., Lambrechts, D., and Wolter, P. (2017). Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome (ViDMe): A Randomized Controlled Trial. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3538-4"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dalle, S., Mortier, L., Corrie, P., Lotem, M., Board, R., Arance, A.M., Meiss, F., Terheyden, P., Gutzmer, R., and Buysse, B. (2021). Long-Term Real-World Experience with Ipilimumab and Non-Ipilimumab Therapies in Advanced Melanoma: The IMAGE Study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08032-y"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1097\/SLA.0000000000005621","article-title":"Follow-up Schedule for Patients with Sentinel Node-Negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial","volume":"276","author":"Moncrieff","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"adv27571","DOI":"10.2340\/actadv.v104.27571","article-title":"Prognostic Value of the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio in Melanoma Patients: A Cohort Study","volume":"104","author":"Ertekin","year":"2024","journal-title":"Acta Derm.-Venereol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:21:28Z","timestamp":1786695688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":132,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162619"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162619","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}